
2 Analytical Characterization *Structural Assessment of Biosimilarity*

Steven A. Berkowitz
Consultant

CONTENTS

2.1	Introduction	16
2.2	Biosimilarity: An Extension of the Concept of Comparability	23
2.3	The Unique Challenges in Making Biosimilars versus Generics from a Physicochemical Perspective	26
2.4	Posttranslational Modifications	27
2.5	The Physicochemical “Window of Consistency” of the Reference Product (RP) and Assessing Biosimilarity	31
2.5.1	Challenges in Assessing the Physicochemical Window of Consistency of an RP in Establishing Biosimilarity	33
2.5.1.1	Potential Analytical Method Bias Effects due to Sample Matrix Differences between the RP and Its Biosimilar.....	34
2.5.1.2	The Impact of Sample Handling and Processing Steps in Conducting Physicochemical Measurements	36
2.5.1.3	Potential Impact of Investigating a Limited Number of RP Lots	37
2.5.1.4	Impact of Different RP Lots Derived from the Same Bioreactor Run versus Different Bioreactor Runs	38
2.5.1.5	RP Sourcing Limitations for Different Regulatory Regions.....	39
2.6	Analytical Physicochemical Characterization Capabilities in Assessing Biopharmaceutical Consistency and Biosimilarity	40
2.6.1	Analytics at the Biochemical Level: Primary Structure	41
2.6.1.1	MS: A Key Primary Structure Tool for Assessing Biopharmaceutical Consistency, Comparability, and Biosimilarity	43
2.6.1.2	Structural Analysis of Glycosylation	47
2.6.1.3	Structural Analysis of Cysteine and Cystine	50